Methods of treatment using TLR7 and/or TLR9 inhibitors
The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
1. A method of treating an autoimmune disease or an inflammatory disease, comprising:
administering to an individual having an autoimmune disease or an inflammatory disease an effective amount of a polynucleotide, wherein the polynucleotide consists of the nucleotide sequence selected from the group consisting of SEQ ID NO:73, SEQ ID NO:134, SEQ ID NO:143 and SEQ ID NO:144, and wherein the polynucleotide contains phosphorothioate linkages.
2. The method of claim 1 , wherein the individual is human.
3. The method of claim 1 , for treating an autoimmune disease.
4. The method of claim 3 , wherein the autoimmune disease is systemic sclerosis.
5. The method of claim 3 , wherein the autoimmune disease is rheumatoid arthritis.
6. The method of claim 3 , wherein the autoimmune disease is dermatomyositis.
7. The method of claim 3 , wherein the autoimmune disease is Sjogren's syndrome.
8. The method of claim 1 , for treating an inflammatory disease.
9. The method of claim 8 , wherein the inflammatory disease is pancreatitis.
10. The method of claim 8 , wherein the inflammatory disease is fatty liver disease.
11. The method of claim 8 , wherein the inflammatory disease is cirrhosis.
12. The method of claim 1 , wherein the polynucleotide is contained in a pharmaceutical composition comprising a pharmaceutically acceptable excipient.
13. The method of claim 12 , wherein the pharmaceutical composition comprises a sterile, isotonic solution.
14. The method of claim 12 , wherein the polynucleotide is single stranded.
15. The method of claim 12 , wherein the polynucleotide is double stranded.
16. The method of claim 12 , wherein the polynucleotide consists of the nucleotide sequence of SEQ ID NO:73.
17. The method of claim 12 , wherein the polynucleotide consists of the nucleotide sequence selected of SEQ ID NO:134.
18. The method of claim 12 , wherein the polynucleotide consists of the nucleotide sequence of SEQ ID NO:143.
19. The method of claim 12 , wherein the polynucleotide consists of the nucleotide sequence of SEQ ID NO:144.